Following the review of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended the following changes for the listing of desmopressin: - removal of desmopressin nasal spray 10 micrograms per dose - addition of desmopressin nasal spray 150 micrograms per actuation - changes to the description of the listing to correctly describe the strength of the formulations in micrograms of desmopressin acetate, and to reflect the delivered amount of nasal spray per actuation, rather than per dose (since a dose may comprise more than one actuation (spray). Following consideration of the submission from the World Federation of Hemophilia which included a request to transfer the current listings of plasma-derived coagulation factors from the complementary to the core list, the Expert Committee recommended that the listing for desmopressin also be transferred from the complementary to the core list.